Combinations and therapies comprising fluorouracil and anlotinib
Screening of FGF19 targets through esophageal oncogene sequencing in parallel with anlotinib solved the problem of fluorouracil resistance of esophageal cancer cells, significantly enhanced the effect of chemotherapy, and provided a synergistic combination therapy.
Patent Information
- Application Number
- CN202410984975.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-22
- Publication Date
- 2024-11-12
AI Technical Summary
Patients with advanced esophageal cancer are resistant to conventional chemotherapy drugs, and there are limited types of existing chemotherapy drugs, and tumor cells are highly resistant to fluorouracil, making it difficult to effectively treat them.
FGF19 was screened as a target by esophageal oncogene sequencing, and it was found that FGF19 amplification caused esophageal cancer cells to resist fluorouracil. The combination of anlotinib significantly enhanced the anti-cancer activity of fluorouracil, and the combination of the two significantly enhanced the anti-cancer effect.
It significantly enhanced the sensitivity of FGF19 to amplify the esophageal cancer cells to fluorouracil, improved the chemotherapy effect, and provided a synergistic combination therapy to enhance the therapeutic effect on esophageal cancer.
Smart Images

Figure CN118924761A_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to combination products, pharmaceutical formulations and kits comprising fluorouracil, and their use in the preparation of a medicament for treating cancer in a patient. Background Art
[0002] At present, clinical intervention measures for esophageal cancer mainly include surgery, radiotherapy, chemotherapy and drug therapy. Chemotherapy runs through the entire process of esophageal cancer treatment, including neoadjuvant chemotherapy, adjuvant chemotherapy, concurrent chemotherapy, palliative chemotherapy, etc. It has been found in clinical practice that many patients with advanced esophageal cancer are insensitive to chemotherapy. The types of chemotherapy drugs currently used for esophageal cancer are also limited. The more widely used ones include fluorouracil and fluorouracil-like drugs, taxanes and platinums. In addition, most patients with advanced esophageal cancer have undergone multiple lines of treatment, and the residual tumor cells after layers of treatment and screening are mostly tumor cells that are resistant to conventional chemotherapy drugs. Therefore, solving the problem of esophageal cancer cells' resistance to conventional chemotherapy drugs is an important topic in the field of esophageal cancer research.
[0003] Therefore, there is an urgent need in the art for a product or method for relieving drug resistance of tumor or cancer cells. Summary of the invention
[0004] To address the deficiencies of the prior art, the inventors of the present application screened new targets for the treatment of esophageal cancer based on the gene sequencing results of clinical esophageal cancer patients; and screened out a suitable variant gene FGF19 through esophageal cancer gene sequencing data. Then, the inventors of the present application analyzed the characteristics of the FGF19 gene in esophageal cancer and its effect on prognosis through the database, and analyzed the potential of FGF19 as a target. Finally, the inventors of the present application found through in vivo and in vitro experiments that FGF19 amplification causes esophageal cancer cells to be resistant to fluorouracil, and that the FGF19 amplified esophageal cancer cell line (KYSE-410FGF19 AM / KYSE-510FGF19 AM ) has decreased chemosensitivity to fluorouracil; while combined use of anlotinib can enhance the chemosensitivity of FGF19 amplified esophageal cancer cells to fluorouracil, and the two have a synergistic effect.
[0005] Thus, the present invention generally provides a combination product or therapy with a synergistic effect, wherein the specific combination is based on fluorouracil and anlotinib. In the combination, anlotinib can significantly enhance the sensitivity of fluorouracil to FGF19 amplified esophageal cancer cells, and the combination of the two has a synergistic effect. Compared with the expected anticancer activity when a single member of the combination therapy is used alone, the combination shows enhanced anticancer activity.
[0006] In one aspect, the present invention relates to the use of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer in a patient.
[0007] In some embodiments, the cancer is an FGF19 amplified cancer.
[0008] In some embodiments, the cancer is esophageal cancer.
[0009] In some embodiments, the esophageal cancer is FGF19 amplified esophageal cancer.
[0010] In some embodiments, the esophageal cancer is esophageal squamous cell carcinoma or esophageal adenocarcinoma.
[0011] In some embodiments, the esophageal cancer is selected from recurrent esophageal cancer, metastatic esophageal cancer, recurrent metastatic esophageal cancer, and advanced metastatic esophageal cancer.
[0012] In one aspect, the present invention relates to a composition comprising the following active ingredients:
[0013] (i) fluorouracil or a pharmaceutically acceptable salt thereof; and
[0014] (ii) anlotinib or a pharmaceutically acceptable salt thereof.
[0015] In one embodiment, the composition consists of (i) fluorouracil or a pharmaceutically acceptable salt thereof; and (ii) anlotinib or a pharmaceutically acceptable salt thereof.
[0016] In one aspect, the present invention relates to a pharmaceutical composition or pharmaceutical preparation comprising the above composition and a pharmaceutically acceptable excipient or carrier.
[0017] In one aspect, the present invention relates to a kit comprising the above composition or the above pharmaceutical composition or pharmaceutical preparation.
[0018] Fluorouracil referred to herein is also known as 5-fluorouracil and has the structural formula:
[0019]
[0020] FGF19 amplification referred to herein has the same meaning as FGF19 gene amplification, covering FGF19 gene copy number amplification and increased expression level, etc. Those skilled in the art also understand how to judge "increase" and / or "amplification", as described in detail in the definition section below, the increase and / or amplification is statistically significant, such as at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more increase and / or amplification, such as copy number amplification.
[0021] According to the FGF19 gene sequence (NM_005117) or the corresponding mRNA and protein sequence, those skilled in the art are familiar with the method for detecting FGF19 amplification. Designing or selecting oligonucleotide probes, primers or antibodies for detecting FGF19 gene amplification and other reagents and methods for implementing the detection are within the technical scope of those skilled in the art.
[0022] As shown in the Examples section below, the increased expression level and / or copy number amplification of the FGF19 gene leads to reduced sensitivity of esophageal cancer cells or patients with esophageal cancer to fluorouracil chemotherapy, and anlotinib can reverse this reduced sensitivity. Fluorouracil combined with anlotinib can show synergistic effects in esophageal cancer with FGF19 gene amplification. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 : The results of gene sequencing of 50 patients with esophageal cancer show the top 16 gene mutations and mutation frequencies. Among them, it shows that the mutation type of FGF19 gene in esophageal cancer is gene amplification, ranking third.
[0024] Figure 2 :Database analysis of FGF19-related features. A. cBi oPortal website analysis of the proportion of FGF19 gene amplification in esophageal cancer datasets; B. GeneMAN IA database analysis of 20 genes related to FGF19; C. STRI NG database analysis of 10 proteins related to FGF19; D. KEGG pathway enrichment analysis of FGF19+20 related genes; E. KEGG pathway enrichment analysis of FGF19+10 related proteins.
[0025] Figure 3 :FGF19 is differentially expressed in esophageal cancer tissues and normal tissues. A. TCGA pan-cancer analysis showed that FGF19 was highly expressed in a variety of cancer tissues; B. FGF19 was significantly highly expressed in esophageal cancer tissues; C. ROC curve of FGF19 expression predicted esophageal cancer tumor tissues drawn using TCGA database (AUC = 0.788); D. ROC curve of FGF19 expression predicted esophageal cancer tumor tissues drawn using TCGA + GTEx database (AUC = 0.914).
[0026] Figure 4 : Successfully constructed an esophageal cancer cell line containing FGF19 gene amplification. A. qPCR experiments and protein immunoblotting experiments confirmed that the FGF19 amplified esophageal cancer cells were successfully constructed (KYSE-410FGF19 AM and KYSE-510FGF19 AM); B. FGF19 gene amplification promotes the proliferation of esophageal cancer cells. The control group was the corresponding empty-loaded esophageal cancer cell lines (KYSE-410CON and KYSE-510CON).
[0027] Figure 5 :Transwell assay determined that FGF19 amplification significantly enhanced the invasion ability of esophageal cancer cells.
[0028] Figure 6 : FGF19 amplification significantly enhanced the migration ability of esophageal cancer. Figure 4 and Figure 5 .
[0029] Figure 7 :The effect of FGF19 amplification on the cell cycle of esophageal cancer cells, and the effect of fluorouracil (5μg / ml) and anlotinib (5μM) treatment on the cell cycle. A. Cell cycle distribution of KYSE-410CON esophageal cancer cells in each treatment group; B. KYSE-410FGF19 AM Cell cycle distribution of esophageal cancer cells in each treatment group; C. Cell cycle distribution of KYSE-510CON esophageal cancer cells in each treatment group; D. KYSE-510FGF19 AM Cell cycle distribution of esophageal cancer cells in each treatment group.
[0030] Figure 8 :FGF19 amplification reduces the sensitivity of esophageal cancer cells to fluorouracil, and anlotinib can enhance the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil. The legends in the bar graph represent from top to bottom: control group / 5-fluorouracil, FGF19 amplification / 5-fluorouracil, FGF19 amplification / 5-fluorouracil + anlotinib (3 μM in the left bar graph and 1 μM in the right bar graph).
[0031] Fig. 9 :FGF19 amplification reduces the sensitivity of esophageal cancer cells to fluorouracil, and FGFR4 specific inhibitor FGF401 enhances the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil. The legends in the bar graph represent from top to bottom: control group / 5-fluorouracil, FGF19 amplification group / 5-fluorouracil, FGF19 amplification / 5-fluorouracil+FGF401 (10μM).
[0032] Fig.10: Exploration of FGF19-FGFR4 downstream signaling pathway. A. Western blotting assay to detect changes in protein expression in different treatment groups; B. CCK8 assay to detect the effect of FGF19 amplification on Wnt pathway inhibition (LGK974 is a Wnt pathway inhibitor). The legends in Figure C represent from top to bottom: control group, 5-fluorouracil (3μg / ml), 5-fluorouracil (3μg / ml) + LGK974 (10μM), 5-fluorouracil (3μg / ml) + anlotinib (3μM in the left column and 1μM in the right column).
[0033] Fig.11 :The nude mouse subcutaneous transplant tumor model verifies the effect of FGF19 amplification on the sensitivity of esophageal cancer cells to fluorouracil chemotherapy. The legends in the left line graph represent from top to bottom: control group / blank control, control group / 5-fluorouracil, FGF19 amplification group / blank control, FGF19 amplification group / 5-fluorouracil, FGF19 amplification group / anlotinib, FGF19 amplification group / 5-fluorouracil+anlotinib.
[0034] Fig.12 :Immunohistochemical staining (Ki 67, CD31, TUNEL) of subcutaneous tumor tissues in nude mice. In Figure B, the groups from top to bottom are: control group / blank control, control group / 5-fluorouracil, FGF19 amplification group / blank control, FGF19 amplification group / 5-fluorouracil, FGF19 amplification group / anlotinib, FGF19 amplification group / 5-fluorouracil+anlotinib.
[0035] Fig.13 : Map of plasmid pcDNA3.1-FGF19. DETAILED DESCRIPTION
[0036] The present invention relates to a combination therapy that exhibits a synergistic effect, wherein the specific combination exhibits enhanced anti-cancer activity in certain types of cancer compared to the expected anti-cancer activity when the individual members of the combination therapy are used alone.
[0037] The present invention discovers and confirms that anlotinib can significantly enhance the sensitivity of fluorouracil to FGF19 amplified esophageal cancer cells, and the combination of the two has a synergistic effect.
[0038] The term "sample" means a material known or suspected to express or contain a biomarker (i.e., FGF19) or a binding agent, such as an antibody specific to a biomarker (i.e., FGF19). The sample may be derived from a biological source ("biological sample"), such as a tissue (e.g., a biopsy sample), an extract, or a cell culture including a cell (e.g., a tumor cell), a cell lysate, and a biological or physiological fluid, such as whole blood, plasma, serum, saliva, cerebrospinal fluid, sweat, urine, milk, peritoneal fluid, etc. The sample obtained from the source or the sample after pretreatment to improve the sample characteristics (e.g., preparing plasma from blood, diluting mucus, etc.) can be used directly. In certain aspects of the present invention, the sample is a human physiological fluid, such as human serum. In certain aspects of the present invention, the sample is a biopsy sample, such as a tumor tissue or cell obtained by tissue examination. In certain aspects of the present invention, the sample is a malignant or normal tissue sample, such as a normal tissue sample adjacent to cancer.
[0039] The terms "subject", "patient" and "individual" are used interchangeably herein and refer to warm-blooded animals, such as mammals. The term includes, but is not limited to, livestock, rodents (such as rats and mice), primates and humans. Preferably, the term refers to humans.
[0040] Fibroblast growth factor 19 (FGF19) was first discovered in the human brain. Its encoding gene is located on chromosome 11q13 and consists of 216 amino acids. It is highly expressed in ileal and gallbladder epithelial cells, but cannot be detected in normal liver. FGF15 is highly expressed in the ileum, jejunum and duodenum of adult mice. It is the mouse homolog of FGF19 and consists of 218 amino acids. It has 51% similarity with human FGF19. This study is based on the human FGF19 gene whose sequence is shown in NCBI No. NM_005117.
[0041] The term "control" should be understood according to the general understanding of those skilled in the art, and represents any useful reference for comparing gene copy number, protein or mRNA level. The control can be any sample, standard, standard curve or level for comparison purposes. The control can be a normal reference sample or reference standard or level. The control can be a blood control sample of the patient himself; the expression of an internal reference gene (such as FGF19) of esophageal cancer such as esophageal squamous cell carcinoma tumor cells themselves; predetermined cells that are relatively insensitive to fluorouracil (e.g., primary esophageal squamous cell carcinoma cells that are relatively insensitive to fluorouracil), such as "normal control" or a previous sample taken from the same subject; a sample from a normal healthy subject, such as a normal cell or normal tissue; a sample (e.g., cell or tissue) from a subject without the disease; or a sample of a purified protein or RNA at a known normal concentration. "Reference standard or level" refers to a value or number derived from a reference sample. "Normal control value" is a predetermined value indicating a non-disease state, for example, a value expected in a healthy control subject. Typically, a normal control value is expressed as a range ("between X and Y"), an upper threshold ("not higher than X"), or a lower threshold ("not lower than X"). For a particular biomarker, a subject with a measurement within the normal control value is often referred to as being "within normal limits" for that biomarker. A normal reference standard or level can be a normal subject who has never suffered from a disease or condition (e.g., cancer). The empty esophageal cancer cell lines (KYSE-410CON and KYSE-510CON) constructed in the examples herein are FGF19 amplified stably transfected esophageal cancer cell lines (KYSE-410FGF19) constructed. AM / KYSE-510FGF19 AM ) control group.
[0042] Compared to a control or standard (e.g., normal levels from healthy esophageal cells, levels at different stages of the disease or levels in other samples from patients, levels of esophageal cancer cells from previous stages of the disease or patients with esophageal cancer that have maintained undiminished sensitivity to fluorouracil), an "increase" or "decrease" in the expression level of a marker in a patient sample or an "amplification" or "deletion" in the copy number can mean a level that is higher or lower than the standard error of the detection assay, preferably at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more of the control or standard, or at most about 1 / 1.1, 1 / 1.25, 1 / 1.5, 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 6, 1 / 7, 1 / 8, 1 / 9 or 1 / 10 or less of the control or standard. Copy number amplification or deletion can be detected by techniques well known in the art, such as high-throughput sequencing as described in the examples, or whole genome sequencing, whole transcriptome sequencing, other second-generation sequencing detection methods, chip detection, droplet digital polymerase chain reaction (ddPCR), etc. as known in the art. FGF19 gene amplification referred to herein means that the copy number of the FGF19 gene is increased or the expression level is increased compared to the above-mentioned control or standard that does not contain amplification, preferably increased or increased by at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more.
[0043] The terms "polypeptide" and "protein" or "protein" are used interchangeably herein to refer to at least one molecular chain of amino acids linked by covalent and / or non-covalent bonds. The term includes peptides, oligopeptides and post-translational modifications of proteins and polypeptides, such as glycosylation, acetylation, phosphorylation, etc. Protein fragments, analogs, mutant proteins or variant proteins, fusion proteins, etc. are also included in the meaning of the term.
[0044] In the present invention, protein fragment refers to a polypeptide having an amino terminal deletion, a carboxyl terminal deletion and / or an intermediate deletion compared to the full-length native protein. The fragment may also contain modified amino acids compared to the native protein. In certain embodiments, the fragment length is about 5-215 amino acids. For example, the fragment length may be at least 5, 6, 8, 10, 14, 20, 50, 70, 100, 110, 150 or 200 amino acids. In one embodiment, the fragment is an immunologically detectable fragment, which preferably comprises at least 6, 7, 8, 10, 12, 15 or 20 consecutive amino acids of a marker polypeptide. The change of protein expression level refers to the expression level compared with the control or standard, at least at least about 1.1,1.25,1.5,2,3,4,5,6,7,8,9 or 10 times or more times of the expression level of the control or standard or at most about 1 / 1.1,1 / 1.25,1 / 1.5,1 / 2,1 / 3,1 / 4,1 / 5,1 / 6,1 / 7,1 / 8,1 / 9 or 1 / 10 or less of the expression level of the control or standard.In this article, due to the amplification of FGF19 gene, its corresponding RNA (such as mRNA) and protein expression or level can also be compared to control group and increase, for example, increase at least about 1.1,1.25,1.5,2,3,4,5,6,7,8,9 or 10 times or more times.In certain embodiments, as used herein, mensuration " protein expression level ", " gene expression " or " gene expression level " include but not limited to mensuration corresponding RNA, albumen or peptide level (or its combination). The present invention is not limited to specific methods and reagents for measuring protein, peptide or RNA levels, all of which are well known in the art.
[0045] Methods for determining the amount or concentration of a protein in a sample are known to the skilled artisan. Such methods include radioimmunoassays, competitive binding assays, Western blot analysis, and ELISA assays. For methods using antibodies, both monoclonal and polyclonal antibodies are suitable. The antibodies may be immunologically specific for a protein, protein epitope, or protein fragment.
[0046] Reagents that can be used to detect the expression level and / or copy number of FGF19 are well known in the art. Such reagents suitable for use in the present invention can be purchased commercially or routinely prepared by methods well known to those skilled in the art.
[0047] As used herein, "treating" cancer refers to administering a combination therapy of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof to a subject suffering from or diagnosed with cancer, to achieve at least one active therapeutic effect, such as reducing the number of cancer cells, reducing tumor size, reducing the rate of cancer cell infiltration into peripheral organs, or reducing the rate of tumor metastasis or tumor growth. Active therapeutic effects in cancer can be measured in many ways (see WA Weber, J. Nucl. Med. 50: 1S-10S (2009)). For example, with respect to tumor growth inhibition, according to NCI standards, T / C ≤ 42% is the minimum level of antitumor activity. T / C < 10% is considered a high level of antitumor activity, where T / C (%) = median tumor volume of treatment / median tumor volume of control × 100. In some cases, the response to the combination therapy described herein is evaluated using RECIST 1.1 criteria or irRC (two-dimensional or one-dimensional), and the treatment achieved by the combination of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof is any one of PR (partial remission), CR (complete remission), OR (objective remission), PFS (progression-free survival), DFS (disease-free survival) and OS (overall survival). PFS (also referred to as "tumor progression time") indicates the length of time that cancer does not grow during and after treatment, and includes the amount of time that the patient experiences CR or PR and the amount of time that the patient experiences SD. DFS refers to the length of time that the patient remains disease-free during and after treatment. OS refers to an increase in life expectancy compared to an untreated individual or patient. In some cases, the response to the combination of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof is any one of PR, CR, PFS, DFS, OR and OS, which is evaluated using RECIST 1.1 response criteria. Combination therapy regimens effective for treating cancer patients according to the present invention may vary depending on a variety of factors, such as the disease state, age, and weight of the patient, and the ability of the therapy to elicit an anti-cancer response in the subject. Therapeutic methods, combinations, and medicaments according to the present disclosure may not be effective in achieving a positive therapeutic effect in every subject, but they should be effective in achieving a positive therapeutic effect in a statistically significant number of subjects, as determined by any statistical test known in the art, such as Student's t-test, chi-square test, or the like. 2 test, U test according to Mann and Whitney, Kruskal-Wallis test (H test), Jonckheere-Terpstra test, and Wilcoxon test.
[0048] The terms "treatment regimen", "dosing regimen" and "administration regimen" are used interchangeably and refer to the dosage and timing of administration of each therapeutic agent in the combination of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof.
[0049] "Tumor" when applied to a subject diagnosed with or suspected of having cancer, refers to a malignant or potentially malignant tumor or mass of tissue of any size, and includes primary tumors and secondary tumors. Solid tumors are abnormal growths or masses of tissue that usually do not contain cysts or fluid areas. Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas.
[0050] "Tumor burden", also known as "tumor load", refers to the total amount of tumor material distributed throughout the body. Tumor burden refers to the total number of cancer cells throughout the body (including lymph nodes and bone marrow) or the total size of one or more tumors. Tumor burden can be determined by various methods known in the art, such as by measuring the size of one or more tumors after removal from a subject (e.g., using calipers), or using imaging techniques (e.g., ultrasound, bone scan, computed tomography (CT) or magnetic resonance imaging (MRI) scans) to measure the size of one or more tumors while in vivo.
[0051] The term "tumor size" refers to the overall size of a tumor, which can be measured as the length and width of the tumor. Tumor size can be determined by various methods known in the art, such as by measuring the size of one or more tumors when removed from a subject, such as using calipers, or when in vivo using imaging techniques, such as bone scans, ultrasound, CT or MRI scans.
[0052] "Unidimensional irRC" refers to the set of criteria described in Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. "Developing a Common Language for Tumor Response to Immunotherapy: Immune-related Response Criteria using Unidimensional measurements," Clin. Cancer Res. 2013, 19(14): 3936–3943). These criteria utilize the longest diameter (cm) of each lesion.
[0053] Fluorouracil or its pharmaceutically acceptable salt, anlotinib or its pharmaceutically acceptable salt in the combination therapy disclosed herein can each be administered alone or in a drug / preparation (also referred to herein as a pharmaceutical composition), which contains a therapeutic agent and one or more pharmaceutically acceptable carriers, excipients and diluents according to standard pharmaceutical practice. Each therapeutic agent can be prepared by formulating a combination of fluorouracil or its pharmaceutically acceptable salt and anlotinib and / or its pharmaceutically acceptable salt, which can be administered simultaneously or separately. In addition, the preparation can be placed in a single package to provide a so-called kit preparation.
[0054] In the combination therapy disclosed herein, fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof can be administered simultaneously (ie, in the same drug), concurrently (ie, administered one immediately after the other in separate drugs in any order), or sequentially in any order. Sequential administration is particularly useful when the therapeutic agents in the combination therapy are in different dosage forms (one agent is a tablet or capsule and the other agent is a sterile liquid) and / or are administered at different dosing schedules, for example, at least daily.
[0055] In some cases, anlotinib or a pharmaceutically acceptable salt thereof is administered before the administration of fluorouracil or a pharmaceutically acceptable salt thereof, while in other cases, anlotinib or a pharmaceutically acceptable salt thereof is administered after the administration of fluorouracil or a pharmaceutically acceptable salt thereof.
[0056] In some cases, at least one therapeutic agent in the combination therapy is administered using the same dosage regimen (dose, frequency, and duration of treatment) that is typically used when the agent is used as a monotherapy for treating the same cancer. In other cases, the patient receives a lower total amount of at least one therapeutic agent in the combination therapy than when the agent is used as a monotherapy, e.g., a smaller dose, a lower frequency of administration, and / or a shorter duration of treatment.
[0057] Each small molecule therapeutic agent in the combination therapy disclosed herein can be orally administered in the form of a solid preparation, such as tablets, granules, fine particles, powder or capsule, or in the form of a liquid, jelly, syrup, etc. Each small molecule therapeutic agent in the combination therapy disclosed herein can be administered parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal, topical and transdermal routes of administration.
[0058] The combination therapies disclosed herein can be used before or after surgery to remove a tumor, and can be used before, during, or after radiation therapy.
[0059] In some cases, the combination therapies disclosed herein are administered to patients who have not been previously treated with a chemotherapeutic agent, i.e., treatment naive. In other cases, the combination therapies are administered to patients who have failed to achieve a sustained response following prior therapy with a chemotherapeutic agent, i.e., treatment experienced.
[0060] The combination therapies disclosed herein are generally used to treat tumors that are large enough to be found by palpation or by imaging techniques known in the art, such as magnetic resonance imaging (MRI), ultrasound, or computerized axial tomography (CAT) scans.
[0061] The combination therapy disclosed herein is preferably administered to human patients with cancers having FGF19 amplification. It is preferred to detect whether FGF19 is amplified in the patient's punctured tumor tissue by whole genome sequencing. Those skilled in the art are familiar with the relevant operations and can select any reasonable detection technology or method. As described above, FGF19 gene amplification as referred to herein may refer to an increase in the number of copies of the FGF19 gene compared to the above-mentioned control or standard that does not contain amplification, preferably an increase of at least about 1.1, 1.25, 1.5, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times or more.
[0062] The dosage regimen (also referred to herein as the dosing regimen) selected for the combination therapy disclosed herein depends on several factors, including the serum or tissue turnover rate of the entity, the level of symptoms, the immunogenicity of the entity, and the accessibility of the target cells, tissues, or organs in the treated individual. Preferably, the dosage regimen maximizes the amount of each therapeutic agent delivered to the patient, consistent with an acceptable level of side effects. Therefore, the dosage and dosing frequency of each chemotherapeutic agent in the combination depends in part on the specific therapeutic agent, the severity of the cancer being treated, and the patient's characteristics. The determination of a suitable dosage regimen can be performed by a clinician, for example, using parameters or factors known in the art that are suspected of affecting treatment or predicting the effects of treatment, and will depend on, for example, the patient's clinical history (e.g., previous therapy), the type and stage of the cancer to be treated, and the biomarkers of the response to one or more therapeutic agents in the combination therapy.
[0063] The chemotherapeutic agent (i.e., fluorouracil or a pharmaceutically acceptable salt thereof) in the combination therapy disclosed herein can be administered by intravenous injection or intravenous drip. The intravenous injection dose is generally 10-20 mg / kg per day based on body weight, for 5-10 consecutive days, with 5-7 g (or even 10 g) per course of treatment. The intravenous drip dose is generally 300-500 mg / m per day based on body surface area. 2 , used continuously for 3-5 days, and each intravenous drip time must not be less than 6-8 hours; during intravenous drip, an infusion pump can be used to continuously administer the drug for 24 hours.
[0064] The recommended dose of anlotinib or its pharmaceutically acceptable salt before fluorouracil or its pharmaceutically acceptable salt can be 12 mg each time, once a day, orally before breakfast. Take the medicine continuously for 2 weeks and stop for 1 week, that is, 3 weeks (21 days) is a course of treatment. Until the disease progresses or intolerable adverse reactions occur. If a dose is missed during medication, confirm that the time from the next dose is less than 12 hours, then no more supplementary doses will be taken. Adverse reactions should be closely monitored during the use of this product, and adjustments should be made according to the adverse reactions so that the patient can tolerate the treatment. Adverse reactions caused by this product can be treated by symptomatic treatment, suspension of medication and / or adjustment of dosage. According to the degree of adverse reactions, it is recommended to adjust the dose under the guidance of a physician. The adjustment plan can be: ① The first dose adjustment: 10 mg, once a day, for 2 consecutive weeks, and stop for 1 week; ② The second dose adjustment: 8 mg, once a day, for 2 consecutive weeks, and stop for 1 week. If the 8mg dose is still intolerable, the drug is permanently discontinued.
[0065] In some cases, the patient is treated with the combination therapy for at least 24 weeks, e.g., eight 3-week cycles. In some cases, treatment with the combination therapy continues until the patient shows evidence of PD or CR.
[0066] In some cases, if the patient has been diagnosed with esophageal cancer, the patient is selected for treatment with a combination therapy disclosed herein.
[0067] The "therapeutic drug" or "combination therapy" for cancer comprises fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof. The drug can be formulated so that each of the two drugs is separate and administered alone or in combination of the two drugs, or administered together by a method suitable for the desired administration, for example, oral, nasal, mucosal, rectal, vaginal, topical, intravenous, intraperitoneal, intradermal, subcutaneous and intramuscular administration, etc.
[0068] Determining the dosage and therefore the timing of administering a therapeutically effective amount of a cancer combination therapy containing a combination of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof is well understood by those of ordinary skill in the art. For example, an initial effective amount can be assumed from cell culture or other in vitro assays. The dosage can be set to produce a circulating concentration or tissue concentration, such as IC 50 Concentrations, etc., are determined by cell culture assays and / or in animal models.
[0069] The method of administration is selected according to the treatment condition and the therapeutic drug. Fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof can be administered by various methods. For example, one or more components can be administered to the subject by any of the following routes: subcutaneous, intravenous, intraperitoneal, intramuscular and systemic administration, and in some cases, direct injection into a specific organ or tumor, etc. Fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof can be administered by a single route, or simultaneously or sequentially by several routes simultaneously as described herein.
[0070] Fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof may be administered once a day, twice a day, several times a day, or further, multiple times a day, depending in particular on the therapeutic indication and the judgment of the prescribing physician.
[0071] The amount necessary for the combination of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof to provide a therapeutic effect can be determined empirically for a specific purpose according to routine procedures. Typically, when administered for therapeutic purposes, a pharmacologically effective dose is administered to a cell or patient. "Pharmacologically effective amount" or "pharmacologically effective dose" refers to an amount sufficient to produce a desired physiological effect or to achieve a desired result (e.g., to reduce or remove one or more symptoms or indications of a disorder or disease, etc., to treat a specific disorder or disease state).
[0072] The combination therapy can be a combination of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof, which can be further combined with other cancer treatments, such as surgical resection, radiotherapy, chemotherapy, immunotherapy, and supportive therapy (e.g., analgesics, diuretics, antidiuretics, antiviral drugs, antibiotics, nutritional supplements, anemia treatment, coagulation therapy, bone therapy, and psychopathology and psychotherapy), etc.
[0073] These and other aspects disclosed herein, including the exemplary specific methods of treatment, medicaments and uses listed below, will be apparent from the teachings contained herein.
[0074] Example
[0075] In order to explain the content of the present invention more clearly, it will be described in detail below with reference to the accompanying drawings and embodiments.
[0076] Example 1 Screening of new therapeutic targets for esophageal cancer based on gene sequencing results of clinical esophageal cancer patients
[0077] In clinical work, we collected clinical data of esophageal cancer patients who underwent gene sequencing. We statistically analyzed the whole genome sequencing results of 50 esophageal cancer patients collected by the Animal Experiment Center of Nanfang Hospital and screened out new therapeutic targets.
[0078] The frequency statistical analysis of the gene sequencing results of 50 patients with esophageal cancer found that the top 16 variant genes were: TP53, CCND1, FGF19, NOTCH1, LRP1B, FAT1, MYC, CDKN2A, NSD1, EP300, CHEK2, ZNF217, PTCH1, DICER1, CBLB, GNAS. The types of gene mutations included: gene mutation, gene amplification, single copy number deletion, and gene fusion. The top three gene mutations and their proportions were: TP53 gene mutation accounted for 88%, CCND1 gene mutation accounted for 48% (among which amplification accounted for 46% and mutation accounted for 2%), and FGF19 gene amplification accounted for 46%. Figure 1 shown.
[0079] We screened out FGF19 as a new target for research.
[0080] Example 2 Database Analysis of FGF19 Gene Characteristics in Esophageal Cancer and Its Effect on Prognosis
[0081] Although the research results based on Example 1 show that FGF19 amplification has the potential to be a new target for precision treatment of esophageal cancer, it is necessary to further clarify whether the new target is significantly highly expressed in tumor tissues and whether it affects the prognosis of esophageal cancer patients. Therefore, this example further analyzes the characteristics of FGF19 in esophageal cancer patients and its effect on the prognosis of esophageal cancer patients through the sequencing results of a large sample size in an online database.
[0082] The proportion of FGF19 amplification in esophageal cancer was analyzed using the esophageal cancer dataset (TCGA, FirehoseLegacy) from the cBioPortal website. Gene-gene and protein-protein interaction network analysis of FGF19 was performed using the GeneMANIA and STRING websites, and pathway enrichment analysis of FGF19 gene-related genes and proteins was performed using KEGG. The differential expression of FGF19 in esophageal cancer tumor tissues and normal tissues was analyzed using the esophageal cancer dataset from the TCGA database. Genes positively and negatively correlated with FGF19 expression in esophageal cancer were screened using the LinkedOmics database, and the biological function enrichment analysis of FGF19 was performed. The clinical characteristics, prognosis analysis, and visualization of the esophageal cancer dataset from the TCGA database were performed using the R language.
[0083] R software was used for analysis. Independent sample t-test was used to analyze the differential expression level of FGF19 mRNA between esophageal cancer tissues and normal tissues in the TCGA database. Pearson chi-square test was used to analyze the correlation between FGF19 expression and clinicopathological characteristics. Kaplan-Meier plot was used for disease-specific survival (DSS) analysis, and log-rank test was used to compare differences. Cox proportional hazards regression model was used for univariate and multivariate analysis. Two-tailed P < 0.05 was considered statistically significant.
[0084] First, we analyzed the mutation of FGF19 gene in esophageal cancer through the database to understand its characteristics in esophageal cancer. We analyzed the TCGA database esophageal cancer data set (TCGA, FirehoseLegacy) through the cBioPortal website and found that FGF19 amplification accounted for 35% in esophageal cancer ( Figure 2 A). Gene-gene and protein-protein interaction network analysis was performed using the GeneMAN IA website and the STRI NG website, and 20 potential target genes interacting with the FGF19 gene were found (FGFR4 / KLB / KL / SDC2 / FGFR1 / FGF20 / FGF5 / FGF17 / FGF22 / FGF16 / FGF23 / FGF8 / FGF18 / FGF6 / FGF9 / FGF3 / FGF7 / FGF4 / FGF10 / FGF1)( Figure 2 B) and 10 potential target proteins (KLB / FGFR1 / FGFR3 / FGFR2 / FGF23 / FGF10 / FGF7 / FGF2 / PLCG1 / FGFR4) ( Figure 2 C) FGF19 and 20 related genes ( Figure 2 D) and 10 related protein-coding genes ( Figure 2 E) KEGG pathway enrichment analysis was performed separately, and it was found that the main enriched signaling pathways related to FGF19 at the gene and protein levels were PI 3K-Akt signaling pathway and MAPK signaling pathway.
[0085] We analyzed the expression of FGF19 in pan-cancer in the TCGA database and found that FGF19 was differentially expressed in various tumor tissues and normal tissues ( Figure 3 A), the expression of FGF19 in esophageal cancer tissues was significantly higher than that in normal tissues ( Figure 3 B). In the process of tumor development, high expression of FGF19 can predict tumor tissue (AUC = 0.788) ( Figure 3 C), TCGA+GTEx database showed that high expression of FGF19 had a high accuracy in predicting tumor tissue (AUC = 0.914) ( Figure 3D). The above results suggest that FGF19 is significantly overexpressed in esophageal cancer tumor tissues and may serve as a new target for the treatment of esophageal cancer.
[0086] Example 3 FGF19 amplification reduces chemotherapy sensitivity of esophageal cancer cells
[0087] Using human esophageal cancer cell lines KYSE-410 and KYSE-510 purchased from Shanghai Meixuan Biotechnology Co., Ltd., we successfully constructed a stably transfected esophageal cancer cell line containing FGF19 amplification (KYSE-410FGF19 AM / KYSE-510FGF19 AM ), and empty vector esophageal cancer cell lines (KYSE-410CON / KYSE-510CON). The plasmid used is pcDNA3.1-FGF19 ( Fig.13 ), the plasmid contains the FGF19 gene inserted downstream of the CMV promoter and carries the puromycin resistance gene as a selection marker. The sequence of the FGF19 gene is the gene sequence shown in NCBI No.: NM_005117, and the gene fragment is synthesized by Jikai Biotechnology Co., Ltd. The empty plasmid is pcDNA3.1-empty, which contains the CMV promoter and the puromycin resistance gene, but no FGF19 gene is inserted. When the cells are cultured to 30-50% confluence, 50μl of virus solution and 8μg / ml polybrene are used for transfection. Fresh culture medium is replaced after 24-48 hours of culture. KYSE-410 cells and KYSE-510 cells are placed in complete culture medium containing 250μg / ml and 450μg / ml G418 for 5-7 days after transfection 48-96 hours later to obtain cells with G418 resistance, and then monoclonal stable transfection cell lines are screened and cultured.
[0088] Real-time quantitative PCR (qPCR) and Western blot were used to verify the mRNA level and protein level, respectively. Figure 4 As shown in A, the stably transfected esophageal cancer cell line containing FGF19 amplification had significantly higher FGF19 expression than the control group.
[0089] It was also found through clone formation experiments that FGF19 amplification promoted the proliferation of esophageal cancer cells. Stably transfected cells were seeded into 6-well culture dishes at a low density (500 cells / well) and cultured for two weeks, during which the culture medium was changed every 3 days. The cells were then fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of clones formed in each culture dish was counted and compared. The results are shown in Figure 2. Figure 4B. The experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001.
[0090] 3.1 FGF19 amplification enhances the invasive ability of esophageal cancer cells
[0091] After successfully constructing the FGF19-amplified esophageal cancer cell line, the effect of FGF19 amplification on the malignant biological characteristics of esophageal cancer cells was further verified. First, the effect of FGF19 amplification on the invasive ability of esophageal cancer cells was observed by Transwell invasion assay. The Transwell device used was purchased from Corning, with a pore size of 8 μm. The number of cells seeded was 5×10 4 Cells / well were inoculated in the upper chamber containing Matrigel (BD Biosciences), and culture medium containing 10% FBS was added to the lower chamber as a chemotactic factor. After 48 hours of culture, the non-migrated cells in the upper chamber were removed, and the migrated cells were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. The number of migrated cells in each well was counted and compared with the control group (i.e., empty esophageal cancer cell line).
[0092] The results showed that the invasion ability of FGF19-amplified esophageal cancer cells (KYSE-410FGF19AM / KYSE-510FGF19AM) was significantly stronger than that of the control group (KYSE-410CON / KYSE-510CON). Figure 5 As shown in the figure, the experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001.
[0093] 3.2 FGF19 amplification enhances the migration ability of esophageal cancer cells
[0094] The cells were cultured at 2 × 10 5The cells were seeded at a density of cells / well in a 6-well plate. When the cells grew to 80-90% confluence, a straight line was drawn on the cell monolayer with a 200μl pipette tip, and then the floating cells were gently washed away with PBS. Serum-free culture medium was added, and photos were taken at 0 hours, 24 hours, 48 hours and 72 hours to record the healing of the scratches. The scratch area was measured using ImageJ software, and the percentage of scratch healing was calculated. The results showed that the migration ability of esophageal cancer cells in the FGF19 amplification group (KYSE-410FGF19AM / KYSE-510FGF19AM) was significantly stronger than that of the control group (KYSE-410CON / KYSE-510CON). The results are as follows Figure 6 As shown in the figure, the experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05, and ** represents P < 0.01.
[0095] 3.3 Effect of FGF19 amplification on the cell cycle of esophageal cancer cells
[0096] Next, we tested the effect of FGF19 amplification on the cell cycle of esophageal cancer cells, as well as the effect of anlotinib (5μM) and fluorouracil (5μg / ml) on the cell cycle of esophageal cancer cells. AM / KYSE-510FGF19 AM There was no significant difference in the cell cycle between the control group (KYSE-410CON / KYSE-510CON), but different drug treatments caused esophageal cancer cells to be blocked in different cell division phases. After fluorouracil treatment of cells, the cell cycle was mainly blocked in the S phase, while after anlotinib treatment of cells, the esophageal cancer cell cycle was mainly blocked in the G2 / M phase. Figure 7 These experimental results indicate that although FGF19 amplification does not significantly affect cell cycle distribution, the effects of 5-FU and anlotinib on the cell cycle are significant.
[0097] 3.4 In vitro verification that FGF19 amplification reduces fluorouracil chemotherapy sensitivity in esophageal cancer cells
[0098] Through the previous experimental results on the effects of FGF19 amplification on the biological characteristics of esophageal cancer cells such as invasion, migration, cell cycle, and apoptosis, we found that the esophageal cancer cells in the control group were sensitive to fluorouracil, and the use of fluorouracil could significantly inhibit the invasion function of the esophageal cancer cells in the control group; FGF19 amplification promoted the invasion and migration of esophageal cancer cells, but the use of fluorouracil had no significant inhibitory effect, while anlotinib or anlotinib combined with fluorouracil could significantly inhibit the invasion and migration of FGF19 amplified esophageal cancer cells. This suggests that FGF19 amplification leads to enhanced malignant biological behavior of esophageal cancer cells, and anlotinib or anlotinib combined with fluorouracil can prevent this process.
[0099] Combined with our clinical research, that is, 4 patients with FGF19 amplification in clinical cases all achieved partial remission (PR) with anlotinib combined with fluorouracil drugs, we speculate that FGF19 amplification leads to fluorouracil resistance in esophageal cancer cells, and the combination of anlotinib can reverse this process.
[0100] To this end, the CCK8 assay was used to determine the effect of FGF19 amplification on the sensitivity of esophageal cancer cells to fluorouracil chemotherapy. AM / KYSE-510FGF19 AM ) were seeded in 96-well plates at a density of 1000 cells / well. After culturing for 24 hours, different concentrations of fluorouracil (0, 0.01, 0.03, 0.1, 0.3, 1, 3 μg / ml) and anlotinib (KYSE-410FGF19AM 3 μM, KYSE-510FGF19AM 1 μM) were added, and treated alone or in combination for 120 hours. Then, 10 μl of CCK8 reagent (Dojindo) was added to each well, and after incubation at 37°C for 2 hours, the absorbance was measured at a wavelength of 450 nm using an enzyme reader.
[0101] The experimental results are consistent with our speculation: compared with the control group (KYSE-410CON / KYSE-510CON), FGF19 amplified esophageal cancer cells (KYSE-410FGF19 AM / KYSE-510FGF19 AM ) decreased the chemosensitivity to fluorouracil, while the combination with anlotinib could enhance the chemosensitivity to fluorouracil of FGF19 amplified esophageal cancer cells, and the two had a synergistic effect. Figure 8As shown in the figure, the experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001.
[0102] 3.5FGF19 amplification reduces fluorouracil chemotherapy sensitivity in esophageal cancer cells via FGF19-FGFR4-AKT signaling pathway
[0103] The results of CCK8 experiments showed that the esophageal cancer cells in the control group (KYSE-410CON / KYSE-510CON) were sensitive to fluorouracil chemotherapy, while the esophageal cancer cells in the FGF19 amplification group (KYSE-410FGF19 AM / KYSE-510FGF19 AM ) are insensitive to chemotherapy using fluorouracil.
[0104] Next, we further explored the molecular mechanism of decreased sensitivity to fluorouracil in FGF19-amplified esophageal cancer cells. It is well known that FGF401 is a specific inhibitor of FGFR4. We used FGF401 to block the downstream transmission of FGF19-FGFR4 signals. The results showed that when fluorouracil was combined with FGF401, the chemotherapy sensitivity of FGF19-amplified esophageal cancer cells to fluorouracil was restored. The above results indicate that FGF19 amplification leads to decreased sensitivity to fluorouracil by enhancing the FGFR4 signal. Therefore, after using FGF401 to specifically block FGFR4, the sensitivity of esophageal cancer cells to fluorouracil was restored. The results are as follows Fig. 9 The experimental comparison results were statistically significant based on the t-test. All P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; **** represents P < 0.0001; ns represents no statistical significance.
[0105] At the same time, we also explored the downstream pathways of FGF19-FGFR4 signaling through Western blot experiments and CCK8 experiments. Combined with the main enrichment signaling pathways of FGF19-related proteins in Example 2, we verified the AKT and MAPK, STAT3, and Wnt signaling pathways through Western blot. The antibodies used for western blotting included p-AKT (Cell Signaling Technology, #4060, 1:1000 dilution), AKT (Cell Signaling Technology, #9272, 1:1000 dilution), p-ERK1 / 2 (Cell Signaling Technology, #4370, 1:1000 dilution), ERK1 / 2 (Cell Signaling Technology, #9102, 1:1000 dilution), p-STAT3 (Cell Signaling Technology, #9145, 1:1000 dilution), STAT3 (Cell Signaling Technology, #9139, 1:1000 dilution), and β-actin (Cell Signaling Technology, #4970, 1:5000 dilution) as the internal control antibody.
[0106] The results showed that the expression levels of p-AKT, p-ERK1 / 2, and p-STAT3 did not change significantly after treatment with fluorouracil alone or in combination with anlotinib. Fig.10 As shown in A; however, after treating esophageal cancer cells with the Wnt pathway inhibitor LGK974, the inhibition efficiency of FGF19 amplified esophageal cancer cells was significantly stronger than that of the control group, as shown in Fig.10 As shown in B, LGK974 can enhance the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil. There is no significant difference in the inhibition of cell proliferation when fluorouracil combined with LGK974 or anlotinib is used to treat FGF19 amplified esophageal cancer cells. Fig.10 As shown in C. Fig.10 The experimental comparison results of B and 10C were statistically significant based on t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; *** represents P < 0.001; ns represents no statistical significance.
[0107] 3.6 In vivo verification of the effect of FGF19 amplification on fluorouracil chemotherapy sensitivity in esophageal cancer cells
[0108] Next, we used a nude mouse subcutaneous transplant tumor model to verify the effect of FGF19 amplification on the sensitivity of esophageal cancer to fluorouracil chemotherapy. We selected 60 female BALB / c nude mice aged 3-4 weeks (purchased from the Animal Experiment Center of Southern Medical University, Guangzhou, Guangdong Province, and raised in the SPF environment of the Animal Experiment Center of Southern Hospital). KYSE-410CON and KYSE-410FGF19AM cells were inoculated subcutaneously on the back of nude mice, with 5×105 cells inoculated per nude mouse. After inoculation, wait until the tumor volume reaches about 150-250mm 3 Drug treatment was started at 1:00 pm. The nude mice were randomly divided into four groups (10 mice in each group): control group, fluorouracil treatment group (50 mg / kg, intraperitoneal injection, twice a week, for 2 weeks), anlotinib treatment group (0.3 mg / kg, gavage, once a day, for 14 days) and fluorouracil combined with anlotinib treatment group (same dosage as before). After the treatment, the nude mice were killed and the subcutaneous tumors were removed for size measurement.
[0109] The results showed that FGF19 amplified esophageal cancer cells (KYSE-410FGF19 AM ) subcutaneous tumors were less sensitive to fluorouracil (50 mg / kg / w×2w) than the subcutaneous transplanted tumors of esophageal cancer cells (KYSE-410CON) in the control group. However, after combined treatment with anlotinib (0.3 mg / kg / d×14d), the sensitivity of FGF19 amplified esophageal cancer cells to fluorouracil was significantly enhanced, showing drug synergy, which is consistent with our in vitro experimental results. Fig.11 The experimental comparison results were statistically significant based on the t-test. All P values were two-sided and P < 0.05 was considered statistically significant. * represents P < 0.05; ** represents P < 0.01; ns represents no statistical significance.
[0110] After drug treatment, the nude mice were killed and the subcutaneous tumors were removed for further immunohistochemical staining. The antibodies used for immunohistochemistry included Ki67 antibody (Cell Signaling Technology, #9027, 1:200 dilution), CD31 antibody (Abcam, ab28364, 1:100 dilution) and TUNEL kit (Roche, #11684795910).
[0111] Immunohistochemistry results showed that the Ki67 positive rate of esophageal cancer cell transplanted tumors in the control group (KYSE-410CON) was significantly decreased after treatment with fluorouracil, while the Ki67 positive rate of esophageal cancer cell transplanted tumors in the FGF19 amplification group (KYSE-410FGF19 AM ) The Ki67 positive rate of transplanted tumors did not decrease significantly after treatment with fluorouracil or anlotinib, but after anlotinib combined with fluorouracil treatment, the FGF19 amplification group esophageal cancer cells (KYSE-410FGF19AM ) The Ki67 positive rate of transplanted tumors was significantly reduced. CD31 staining indicated that tumor blood vessels were positive in the transplanted tumor tissues. After the control group and the amplification group were treated with fluorouracil, there was no significant change in CD31 staining. After the esophageal cancer cells in the FGF19 amplification group were treated with anlotinib combined with fluorouracil, the esophageal cancer cells in the FGF19 amplification group (KYSE-410FGF19 AM )CD31 staining of transplanted tumors was significantly reduced. TUNEL staining showed little difference among the groups, but the positive rate of TUNEL staining was significantly increased after esophageal cancer cells in the FGF19 amplification group were treated with fluorouracil combined with anlotinib.
[0112] The above results show that fluorouracil can significantly inhibit the proliferation of esophageal cancer cells in the control group, while fluorouracil has no significant inhibitory effect on the proliferation of esophageal cancer cells in the FGF19 amplification group. However, the combination of fluorouracil and anlotinib can not only significantly inhibit the proliferation of esophageal cancer cells in the FGF19 amplification group, but also inhibit angiogenesis and promote apoptosis. These results prove that FGF19 amplification significantly inhibits the sensitivity of esophageal cancer cells to fluorouracil, and anlotinib can significantly enhance the sensitivity of fluorouracil to FGF19 amplified esophageal cancer cells. The combination of the two has a synergistic effect. Fig.12 The experimental comparison results were statistically significant based on the t-test, all P values were two-sided, and P < 0.05 was considered statistically significant. * represents P < 0.05; ns represents no statistical significance.
[0113] 3.7 Conclusion
[0114] We conducted functional experiments to understand the effect of FGF19 amplification on the malignant biological characteristics of esophageal cancer cells. The results showed that FGF19 gene amplification promoted the proliferation, migration and invasion of esophageal cancer cells and reduced the sensitivity of esophageal cancer cells to fluorouracil.
[0115] This part of the study showed that FGF19 amplification reduced the chemosensitivity of esophageal cancer cells to fluorouracil; this decreased sensitivity could be reversed by anlotinib, and the combination of the two had a synergistic effect.
[0116] According to the present disclosure, all uses, products and methods disclosed and claimed herein can be prepared and implemented without excessive experimentation. Those skilled in the art can modify and change the technical solutions and contents disclosed in the present invention according to practical needs, but these modifications and changes do not deviate from the concept, spirit and scope of the present disclosure. All such modifications and changes are obvious to those skilled in the art and are within the scope of protection defined by the claims of the present application.
Claims
1. Use of fluorouracil or a pharmaceutically acceptable salt thereof and anlotinib or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer in a patient.
2. The use according to claim 1, wherein the cancer is a FGF19 amplified cancer.
3. The use according to claim 1, wherein the cancer is esophageal cancer. The use according to claim 3, wherein the esophageal cancer is FGF19 amplified esophageal cancer. The use according to claim 3, wherein the esophageal cancer is esophageal squamous cell carcinoma or esophageal adenocarcinoma.
6. The use according to claim 3, wherein the esophageal cancer is selected from recurrent esophageal cancer, metastatic esophageal cancer, recurrent metastatic esophageal cancer and advanced metastatic esophageal cancer.
7. A composition comprising or consisting of the following active ingredients composition: (i) fluorouracil or a pharmaceutically acceptable salt thereof; and (ii) anlotinib or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical preparation comprising the composition according to claim 7 and a pharmaceutically acceptable excipient or carrier.
9. A medicine kit comprising the composition of claim 7 or the pharmaceutical composition of claim 8.
